Siriporn PEANSUKMANEE, Siriwan TANGYUENYONG, Siriwan ONGCHAI

Effect of sesamin on protection of equine articular cartilage degradation in vitro

Black sesame seed is a potential herbal medicine for osteoarthritis treatment as it contains sesamin, which has antiinflammatory properties and has demonstrated chondroprotective effects in many species. Horses are particularly susceptible to osteoarthritis. Inflammatory mediators and matrix metalloproteinase are important factors causing cartilage degradation. This study aimed to investigate the protective potential of sesamin (0.5-2.0 μM) against interleukin (IL)-1ß-induced equine cartilage explant degradation. The cartilage degradation was monitored by measuring the release of cartilage matrix molecules in culture media including sulfatedglycosaminoglycans and hyaluronan by calorimetric assay and ELISA assay, respectively. The remaining contents of collagen and uronic acid (UA) within the explant tissue were assessed by hydroxyproline assay and UA assay, respectively. Cartilage-degrading enzymes MMP-2 and MMP-3 were evaluated by gelatin zymography and ELISA assay, respectively. The results indicated that sesamin suppressed IL-1ß-induced equine cartilage degradation by reducing the levels of sulfated-glycosaminoglycans and hyaluronan, and preserving the contents of UA and collagen within the explant tissues. The activity of MMP-2 and the quantity of MMP-3 were also suppressed by sesamin. The chondroprotective efficacy of sesamin was comparable to that of diacerein, an antiarthritic drug. Lactate dehydrogenase assay showed that sesamin at concentrations of up to 2 mM did not cause cytotoxicity to chondrocytes in cartilage explants. These results may lead to new options for osteoarthritis treatment in horses.

Keywords:

Sesamin equine articular cartilage, cartilage degradation, chondroprotection,

PDF

___

1. Wallin L, Strandberg E, Philipson J, Dalin G. Estimates of longevity and causes of culling and death in Swedish warmblood and coldblood horses. Livestock Production Science 2000; 63 (3): 275-289. doi: 10.1016/S0301-6226(99)00126-8
2. McIlwraith CW. Traumatic joint injuries and disease: intraarticular fractures amenable to treatment and in which the horse can be returned to athletic activity. In: Stashak TS (editor). Lameness in The Horse; An In-Depth Short Course for the Horseman. 1st ed. Boulder, CO, USA: Equine Sciences of Colorado State University; 1997. pp. 39-42.
3. Kubota E, Imamura H, Kubota T, Shibata T, Murakami KI. Interleukin 1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. Journal of Oral and Maxillofacial Surgery 1997; 55 (1): 20-27. doi: 10.1016/S0278-2391(97)90438-9
4. McIlwraith CW. General pathobiology of the joint and response to injury. In: McIlwraith CW, Trotter GW (editors). Joint Diseases in the Horse. 1st ed. Philadelphia, PA, USA: W.B. Saunders; 1996. pp. 51-54.
5. Clegg PD, Coughlan AR, Riggs CM, Carter SD. Matrix metalloproteinase 2 and 9 in equine synovial fluids. Equine Veterinary Journal 1997; 29 (5): 343-348. doi: 10.1111/j.2042- 3306.1997.tb03137.x
6. Clegg PD, Mobasheri A. Chondrocyte apoptosis, inflammatory mediators and equine osteoarthritis. The Veterinary Journal 2003; 166 (1): 3-4. doi: 10.1016/S1090-0233(02)00270-8
7. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B et al. Matrix metalloproteinases; a review. Critical Reviews in Oral Biology & Medicine 1993; 4 (2): 197- 250. doi: 10.1177/10454411930040020401
8. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Annals of the Rheumatic Diseases 2000; 59 (6): 455-461. doi: 10.1136/ard.59.6.455
9. Mehraban F, Kuo SY, Riera H, Chang C, Moskowitz RW. Prostromelysin and procollagenase genes are differentially UP-regulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. Arthritis & Rheumatology 1994; 37 (8): 1189-1197. doi: 10.1002/art.1780370813
10. Jeng KCG, Hou RCW. Sesamin and sesamolin: nature’s therapeutic lignans. Current Enzyme Inhibition 2005; 1 (1): 11-20. doi: 10.2174/1573408052952748
11. Wu WH, Wang SH, Kuan II, Kao YS, Wu PJ et al. Sesamin attenuates intercellular cell adhesion molecule-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in apolipoprotein-E-deficient mice. Molecular Nutrition & Food Research 2010; 54 (9): 1340-1350. doi: 10.1002/ mnfr.200900271
12. Utsunomiya T, Chavali SR, Zhong WW, Forse RA. Effects of sesamin-supplemented dietary fat emulsions on the ex vivo production of lipopolysaccharide-induced prostanoids and tumor necrosis factor alpha in rats. American Journal of Clinical Nutrition 2000; 72 (3): 804-808. doi: 10.1093/ajcn/72.3.804
13. Utsumomiya T, Shimada M, Rikimaru T, Hasegawa H, Yamashita Y et al. Antioxidant and anti-inflammatory effects of a diet supplemented with sesamin on hepatic ischemiareperfusion injury in rats. Hepato-Gastroenterology 2003; 50 (53): 1609-1613.
14. Cui Y, Hou X, Chen J, Xie L, Yang L et al. Sesamin inhibits bacterial formylpeptide-induced inflammatory responses in a murine air-pouch model and in THP-1 human monocytes. Journal of Nutrition 2010; 140 (2): 377-381. doi: 10.3945/ jn.109.117804
15. Jeng KC, Hou RC, Wang JC, Ping LI. Sesamin inhibits lipopolysaccharide-induced cytokine production by suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B. Immunology Letters 2005; 97 (1): 101- 106. doi: 10.1016/j.imlet.2004.10.004
16. Phitak T. Molecular investigation of phytochemicals having effects on human chondrocyte metabolism. PhD, Chiang Mai University, Chiang Mai, Thailand, 2010.
17. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochimica et Biophysica Acta 1986; 883 (2): 173-177. doi: 10.1016/0304-4165(86)90306-5
18. Pothacharoen P, Choocheep K, Pitak T, Pompimon W, Premanode B et al. Effect of Alpinia galanga extract on cartilage degradation and on gene expression in human chondrocyte and synovial fibroblast metabolism. Central European Journal of Biology 2006; 1 (3): 430-450. doi: 10.2478/s11535-006-0030-6
19. Hoemann CD, Sun J, Chrzanowski V, Buschmann MD. A multivalent assay to detect glycosaminoglycan, protein, collagen, RNA, and DNA content in milligram samples of cartilage or hydrogel-based repair cartilage. Analytical Biochemistry 2002; 300 (1): 1-10. doi: 10.1006/abio.2001.5436
20. Ito A, Nose T, Takahashi S, Mori Y. Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Letters 1995; 360 (1): 75-79. doi: 10.1016/0014-5793(95)00085-N
21. Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, MartelPelletier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritic and Cartilage 2000; 8 (3): 186-196. doi: 10.1053/ joca.1999.0289
22. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. Journal of Rheumatology 1998; 25 (4): 753-762.
23. Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerhein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis and Cartilage 1999; 7 (3): 272-280. doi: 10.1053/joca.1998.0201
24. Korzeniewski C, Callenwaert DM. An enzyme-release assay for natural cytotoxicity. Journal of Immunological Methods 1983; 64 (3): 313-320. doi: 10.1016/0022-1759(83)90438-6